RU2011146654A - Способы лечения рака яичников с применением конъюгированного средства - Google Patents
Способы лечения рака яичников с применением конъюгированного средства Download PDFInfo
- Publication number
- RU2011146654A RU2011146654A RU2011146654/15A RU2011146654A RU2011146654A RU 2011146654 A RU2011146654 A RU 2011146654A RU 2011146654/15 A RU2011146654/15 A RU 2011146654/15A RU 2011146654 A RU2011146654 A RU 2011146654A RU 2011146654 A RU2011146654 A RU 2011146654A
- Authority
- RU
- Russia
- Prior art keywords
- specified
- malignant tumor
- patient
- conjugate
- seq
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Abstract
1. Способ лечения пациента со злокачественной опухолью, которая происходит из яичника, указанный способ включает введение указанному пациенту эффективного количества конъюгата, содержащего:(а) противоопухолевое средство; и(б) полипептид, содержащий аминокислотную последовательность, по крайней мере, на 80% идентичную TFFYGGSRGKRNNFKTEEY (SEQ ID NO:97), где указанный полипептид конъюгирован с указанным противоопухолевым средством.2. Способ по п.1, в котором противоопухолевое средство выбрано из группы, состоящей из паклитаксела, винбластина, винкристина, этопозида, доксорубицина циклофосфамида, таксотера, мелфалана и хлорамбуцила.3. Способ по п.2, в котором указанное противоопухолевое средство представляет собой паклитаксел.4. Способ по любому из пп.1-3, в котором указанный полипептид содержит аминокислотную последовательность, по крайней мере, на 90% идентичную последовательности SEQ ID NO:97.5. Способ по п.4, в котором указанный полипептид содержит аминокислотную последовательность SEQ ID NO:97.6. Способ по п.5, в котором указанный полипептид состоит из аминокислотной последовательности SEQ ID NO:97.7. Способ по п.1, в котором указанный конъюгат вводят в дозе от 100 мг/ми 2000 мг/м.8. Способ по п.7, в котором указанный конъюгат вводят в дозе 300 мг/мдо 1000 мг/м.9. Способ по п.1, в котором указанный конъюгат вводят внутривенно.10. Способ по п.1, в котором указанная злокачественная опухоль метастазировала по крайней мере, в одно место вне яичника и указанный способ эффективен в лечении указанных метастазов.11. Способ по п.10, в котором указанная злокачественная опухоль метастазировала, по крайней мере, в одно место вне головного мозга указанного пациента.12. Способ по
Claims (24)
1. Способ лечения пациента со злокачественной опухолью, которая происходит из яичника, указанный способ включает введение указанному пациенту эффективного количества конъюгата, содержащего:
(а) противоопухолевое средство; и
(б) полипептид, содержащий аминокислотную последовательность, по крайней мере, на 80% идентичную TFFYGGSRGKRNNFKTEEY (SEQ ID NO:97), где указанный полипептид конъюгирован с указанным противоопухолевым средством.
2. Способ по п.1, в котором противоопухолевое средство выбрано из группы, состоящей из паклитаксела, винбластина, винкристина, этопозида, доксорубицина циклофосфамида, таксотера, мелфалана и хлорамбуцила.
3. Способ по п.2, в котором указанное противоопухолевое средство представляет собой паклитаксел.
4. Способ по любому из пп.1-3, в котором указанный полипептид содержит аминокислотную последовательность, по крайней мере, на 90% идентичную последовательности SEQ ID NO:97.
5. Способ по п.4, в котором указанный полипептид содержит аминокислотную последовательность SEQ ID NO:97.
6. Способ по п.5, в котором указанный полипептид состоит из аминокислотной последовательности SEQ ID NO:97.
7. Способ по п.1, в котором указанный конъюгат вводят в дозе от 100 мг/м2 и 2000 мг/м2.
8. Способ по п.7, в котором указанный конъюгат вводят в дозе 300 мг/м2 до 1000 мг/м2.
9. Способ по п.1, в котором указанный конъюгат вводят внутривенно.
10. Способ по п.1, в котором указанная злокачественная опухоль метастазировала по крайней мере, в одно место вне яичника и указанный способ эффективен в лечении указанных метастазов.
11. Способ по п.10, в котором указанная злокачественная опухоль метастазировала, по крайней мере, в одно место вне головного мозга указанного пациента.
12. Способ по п.10, в котором указанная злокачественная опухоль метастазировала вне области таза указанного пациента.
13. Способ по п.10, в котором указанная злокачественная опухоль метастазировала в головной мозг, легкие, печень или их сочетание.
14. Способ по п.10, в котором указанная злокачественная опухоль метастазировала в лимфатическую систему.
15. Способ по п.1, в котором указанная злокачественная опухоль включает в себя клетки идентифицируемые как резистентные к действию лекарственных средств.
16. Способ по п.15, в котором указанная злокачественная клетка экспрессирует MDR1.
17. Способ по п.15 или 16, в котором указанные клетки резистентны к лечению пакпитакселом или к лечению производным таксана.
18. Способ по п.1, в котором указанный способ дополнительно включает применение другой противоопухолевой терапии.
19. Способ по п.1, в котором указанный пациент ранее принимал другое химиотерапевтическое средство.
20. Способ по п.19, в котором указанная злокачественная опухоль является резистентной к указанному ранее принимаемому химиотерапевтическому средству.
21. Способ по п.19 или 20, в котором указанное ранее принимаемое химиотерапевтическое средство представляет собой паклитаксел, средство на основе платины, алкилирующий агент или их сочетание.
22. Способ по п.21, в котором указанное средство на основе платины представляет собой карбоплатин или цисплатин.
23. Способ по п.21, в котором указанный пациент ранее получал комбинированную терапию карбоплатин-паклитакселом.
24. Способ по п.1, в котором указанная злокачественная опухоль представляет собой эпителиальную карциному яичников, или аденокарциному яичников, или ее метастазирующую форму.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17104009P | 2009-04-20 | 2009-04-20 | |
US61/171,040 | 2009-04-20 | ||
PCT/CA2010/000618 WO2010121379A1 (en) | 2009-04-20 | 2010-04-20 | Treatment of ovarian cancer using an anticancer agent conjugated to an angiopep-2 analog |
Publications (1)
Publication Number | Publication Date |
---|---|
RU2011146654A true RU2011146654A (ru) | 2013-05-27 |
Family
ID=43010638
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2011146654/15A RU2011146654A (ru) | 2009-04-20 | 2010-04-20 | Способы лечения рака яичников с применением конъюгированного средства |
Country Status (12)
Country | Link |
---|---|
US (1) | US9173891B2 (ru) |
EP (1) | EP2421562B1 (ru) |
JP (1) | JP2012524030A (ru) |
CN (1) | CN102510759A (ru) |
AU (1) | AU2010239069B2 (ru) |
BR (1) | BRPI1015295A2 (ru) |
CA (1) | CA2759129C (ru) |
ES (1) | ES2729261T3 (ru) |
MX (1) | MX2011011023A (ru) |
RU (1) | RU2011146654A (ru) |
WO (1) | WO2010121379A1 (ru) |
ZA (1) | ZA201107626B (ru) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0406647A (pt) | 2003-01-06 | 2005-12-06 | Angiochem Inc | Método para transportar um composto através da barreira sanguìnea do cérebro |
US20090016959A1 (en) * | 2005-02-18 | 2009-01-15 | Richard Beliveau | Delivery of antibodies to the central nervous system |
SI2233156T1 (sl) * | 2005-07-15 | 2013-09-30 | Angiochem Inc. | Uporaba polipeptidov aprotinina kot nosilce v farmacevtskih konjugatih |
CA2666841A1 (en) | 2006-10-19 | 2008-04-24 | Angiochem, Inc. | Compounds for stimulating p-glycoprotein function and uses thereof |
US9365634B2 (en) | 2007-05-29 | 2016-06-14 | Angiochem Inc. | Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues |
US8921314B2 (en) | 2008-10-15 | 2014-12-30 | Angiochem, Inc. | Conjugates of GLP-1 agonists and uses thereof |
CN102307904A (zh) | 2008-12-05 | 2012-01-04 | 安吉奥开米公司 | 神经降压素或神经降压素类似物的缀合物及其用途 |
JP2012512185A (ja) | 2008-12-17 | 2012-05-31 | アンジオケム インコーポレーテッド | 膜1型マトリックス金属タンパク質阻害剤およびその使用 |
CA2759129C (en) | 2009-04-20 | 2018-12-11 | Angiochem Inc. | Treatment of ovarian cancer using an anticancer agent conjugated to an angiopep-2 analog |
AU2010268726A1 (en) | 2009-07-02 | 2012-01-19 | Angiochem Inc. | Multimeric peptide conjugates and uses thereof |
JP2015526434A (ja) | 2012-08-14 | 2015-09-10 | アンジオケム インコーポレーテッド | ペプチド−デンドリマーコンジュゲート及びその使用 |
AU2013302273A1 (en) * | 2012-08-14 | 2015-02-19 | Angiochem Inc. | Conjugates including an antibody moiety, a polypeptide that traverses the blood-brain barrier, and a cytotoxin |
US20160213760A1 (en) * | 2012-11-12 | 2016-07-28 | Angiochem Inc. | Aprotinin-derived polypeptide-antibody conjugates |
CN105585614B (zh) * | 2014-10-24 | 2019-06-07 | 中国科学技术大学 | 用于淀粉样蛋白显像的血管肽及其衍生物 |
WO2016061801A1 (zh) * | 2014-10-24 | 2016-04-28 | 中国科学技术大学 | 用于淀粉样蛋白显像的血管肽及其衍生物 |
WO2016205367A1 (en) | 2015-06-15 | 2016-12-22 | Angiochem Inc. | Methods for the treatment of leptomeningeal carcinomatosis |
CA3109702A1 (en) | 2018-08-13 | 2020-02-20 | Signablok, Inc. | Peptides and compositions for targeted treatment and imaging |
EP4000613A1 (en) | 2020-11-19 | 2022-05-25 | Polyphor Ag | Pharmaceutical combinations comprising a peptide cxcr4 inhibitor and a taxane for treating cancer |
JP2023549921A (ja) | 2020-11-19 | 2023-11-29 | スペクシス アーゲー | がんを治療するためのペプチドcxcr4阻害剤およびタキサンを含む医薬組み合わせ |
EP4223292A1 (en) | 2022-02-07 | 2023-08-09 | Cellestia Biotech AG | Pharmaceutical combinations for treating cancer |
Family Cites Families (182)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4671958A (en) | 1982-03-09 | 1987-06-09 | Cytogen Corporation | Antibody conjugates for the delivery of compounds to target sites |
ZA871844B (en) | 1986-03-13 | 1988-05-25 | Biotechnology Pty Ltd | Method of assay of inhibin |
US4902505A (en) | 1986-07-30 | 1990-02-20 | Alkermes | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
US4801575A (en) | 1986-07-30 | 1989-01-31 | The Regents Of The University Of California | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
US4904768A (en) | 1987-08-04 | 1990-02-27 | Bristol-Myers Company | Epipodophyllotoxin glucoside 4'-phosphate derivatives |
GB2208511A (en) | 1987-08-07 | 1989-04-05 | Bayer Ag | Variants of bovine pancreatic trypsin inhibitor produced by recombinant dna technology |
US4942184A (en) | 1988-03-07 | 1990-07-17 | The United States Of America As Represented By The Department Of Health And Human Services | Water soluble, antineoplastic derivatives of taxol |
US5632990A (en) | 1988-04-22 | 1997-05-27 | Cancer Research Campaign Tech. Ltd. | Treatment for tumors comprising conjugated antibody A5B7 and a prodrug |
US5258499A (en) | 1988-05-16 | 1993-11-02 | Vestar, Inc. | Liposome targeting using receptor specific ligands |
US5028697A (en) | 1988-08-08 | 1991-07-02 | Eli Lilly And Company | Cytotoxic antibody conjugates of hydrazide derivatized methotrexate analogs via simple organic linkers |
US5169933A (en) | 1988-08-15 | 1992-12-08 | Neorx Corporation | Covalently-linked complexes and methods for enhanced cytotoxicity and imaging |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5948634A (en) | 1988-12-21 | 1999-09-07 | The General Hospital Coporation | Neural thread protein gene expression and detection of alzheimer's disease |
DE3912638A1 (de) | 1989-04-18 | 1990-10-31 | Bayer Ag | Gentechnologisch hergestellte homologe des alzheimer protease inhibitors, wirtstaemme sowie expressionsvektoren fuer ihre herstellung und ihre verwendung als arzneimittel |
US5126249A (en) | 1989-05-09 | 1992-06-30 | Eli Lilly And Company | Enzymatic removal of a protein amino-terminal sequence |
US6020145A (en) | 1989-06-30 | 2000-02-01 | Bristol-Myers Squibb Company | Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96 |
US6475781B1 (en) | 1990-05-17 | 2002-11-05 | Dana-Farber Cancer Institute, Inc. | Trans-dominant suppressor genes for oligomeric proteins |
US5714167A (en) | 1992-06-15 | 1998-02-03 | Emisphere Technologies, Inc. | Active agent transport systems |
GB9017008D0 (en) | 1990-08-02 | 1990-09-19 | Erba Carlo Spa | Process for the enzymatic preparation of basic fibroblast growth factor |
US6495513B1 (en) | 1991-03-11 | 2002-12-17 | Curis, Inc. | Morphogen-enhanced survival and repair of neural cells |
US5955444A (en) | 1991-08-09 | 1999-09-21 | Massachusetts Institute Of Technology | Method of inhibiting abnormal tau hyper phosphorylation in a cell |
US5627270A (en) | 1991-12-13 | 1997-05-06 | Trustees Of Princeton University | Glycosylated steroid derivatives for transport across biological membranes and process for making and using same |
US5204354A (en) | 1992-02-14 | 1993-04-20 | Merck & Co., Inc. | Substituted quinazolinones as neurotensin antagonists useful in the treatment of CNS disorders |
GB9213077D0 (en) | 1992-06-19 | 1992-08-05 | Erba Carlo Spa | Polymerbound taxol derivatives |
CA2145517A1 (en) | 1992-09-25 | 1994-04-14 | Ignace Lasters | Bovine pancreatic trypsin inhibitor derived inhibitors of factor viia - tissue factor complex |
EP0599303A3 (en) | 1992-11-27 | 1998-07-29 | Takeda Chemical Industries, Ltd. | Peptide conjugate |
WO1994019692A1 (en) | 1993-02-18 | 1994-09-01 | The General Hospital Corporation | Alzheimer's disease therapeutics |
WO1996031531A2 (en) | 1995-04-04 | 1996-10-10 | Advanced Bioconcept, Inc. | Fluorescent peptides |
ZA963619B (en) | 1995-05-08 | 1996-11-22 | Scios Inc | Protease inhibitor peptides |
KR19990008458A (ko) | 1995-05-08 | 1999-01-25 | 쉬어러 피터 알. | 쿠니츠(kunitz) 타입 프로테아제 억제 물질 |
AU5908296A (en) | 1995-05-31 | 1996-12-24 | Fred Hutchinson Cancer Research Center | Compositions and methods for targeted delivery of effector m olecules |
US5780265A (en) | 1995-06-05 | 1998-07-14 | Genentech, Inc. | Kunitz type plasma kallikrein inhibitors |
AU6267896A (en) | 1995-06-07 | 1996-12-30 | Imclone Systems Incorporated | Antibody and antibody fragments for inhibiting the growth oftumors |
DE69735996T2 (de) | 1996-03-11 | 2007-02-15 | Bayer Corp. | Menschlicher bikunin |
AU2409397A (en) | 1996-04-24 | 1997-11-12 | Rijksuniversiteit Te Groningen | A prokaryotic protein having functional and structural homology with the uman p-glycoprotein encoded by the mdr-1 gene, nucleic acids encoding and cells expressing said protein |
JP2000509394A (ja) | 1996-05-01 | 2000-07-25 | アンティバイラルズ インコーポレイテッド | 細胞膜を横切って物質を輸送するためのポリペプチド結合体 |
DE19636889A1 (de) | 1996-09-11 | 1998-03-12 | Felix Dr Kratz | Antineoplastisch wirkende Transferrin- und Albuminkonjugate zytostatischer Verbindungen aus der Gruppe der Anthrazykline, Alkylantien, Antimetabolite und Cisplatin-Analoga und diese enthaltende Arzneimittel |
US6056973A (en) | 1996-10-11 | 2000-05-02 | Sequus Pharmaceuticals, Inc. | Therapeutic liposome composition and method of preparation |
AU4907897A (en) | 1996-10-11 | 1998-05-11 | Sequus Pharmaceuticals, Inc. | Therapeutic liposome composition and method |
US5948750A (en) | 1996-10-30 | 1999-09-07 | Merck & Co., Inc. | Conjugates useful in the treatment of prostate cancer |
EP0975792B1 (en) | 1997-03-04 | 2007-10-10 | Savient Pharmaceuticals, Inc. | Isolation of tissue specific peptide ligands and their use for targeting pharmaceuticals to organs |
US6126965A (en) | 1997-03-21 | 2000-10-03 | Georgetown University School Of Medicine | Liposomes containing oligonucleotides |
GB9705903D0 (en) | 1997-03-21 | 1997-05-07 | Elliott Gillian D | VP22 Proteins and uses thereof |
AU734827B2 (en) | 1997-05-21 | 2001-06-21 | Board Of Trustees Of The Leland Stanford Junior University | Composition and method for enhancing transport across biological membranes |
US6391305B1 (en) | 1997-09-10 | 2002-05-21 | Merck & Co., Inc. | Conjugates useful in the treatment of prostate cancer |
US6093692A (en) | 1997-09-25 | 2000-07-25 | The University Of Southern California | Method and compositions for lipidization of hydrophilic molecules |
US6475481B2 (en) | 1997-11-18 | 2002-11-05 | Canji Inc | Purging of stem cell products |
WO1999026657A1 (en) | 1997-11-25 | 1999-06-03 | Musc Foundation For Research Development | Inhibitors of nitric oxide synthase |
US5981564A (en) | 1998-07-01 | 1999-11-09 | Universite Laval | Water-soluble derivatives of paclitaxel, method for producing same and uses thereof |
GB9814527D0 (en) | 1998-07-03 | 1998-09-02 | Cyclacel Ltd | Delivery system |
US6703381B1 (en) | 1998-08-14 | 2004-03-09 | Nobex Corporation | Methods for delivery therapeutic compounds across the blood-brain barrier |
US5922754A (en) | 1998-10-02 | 1999-07-13 | Abbott Laboratories | Pharmaceutical compositions containing paclitaxel |
WO2000050059A1 (en) | 1999-02-24 | 2000-08-31 | The Uab Research Foundation | Taxane derivatives for targeted therapy of cancer |
GB9911683D0 (en) | 1999-05-19 | 1999-07-21 | Chiron Spa | Antigenic peptides |
US6180607B1 (en) | 1999-08-05 | 2001-01-30 | Christopher Davies | Protein having proteinase inhibitor activity |
US6713454B1 (en) | 1999-09-13 | 2004-03-30 | Nobex Corporation | Prodrugs of etoposide and etoposide analogs |
WO2001021584A1 (en) | 1999-09-24 | 2001-03-29 | Genentech, Inc. | Tyrosine derivatives |
US6136846A (en) | 1999-10-25 | 2000-10-24 | Supergen, Inc. | Formulation for paclitaxel |
DE19953696A1 (de) | 1999-11-09 | 2001-05-10 | Alexander Cherkasky | Selektive proteolytische Synzyme (SPS) |
CA2355334A1 (en) | 2000-10-16 | 2002-04-16 | Procyon Biopharma Inc. | Pharmaceutical preparations and methods for inhibiting tumors |
AU2002239282A1 (en) | 2000-11-28 | 2002-06-11 | Transform Pharmaceuticals, Inc. | Pharmaceutical formulations comprising paclitaxel, derivatives, and pharmaceutically acceptable salts thereof |
EP1355942B1 (en) | 2000-12-07 | 2008-08-27 | Eli Lilly And Company | Glp-1 fusion proteins |
IL157993A0 (en) | 2001-03-23 | 2004-03-28 | Napro Biotherapeutics Inc | Molecular conjugates for use in cancer treatment and methods for the preparation thereof |
AU2002303431C1 (en) | 2001-04-19 | 2008-03-06 | The Regents Of The University Of California | Methods and composition for the production of orthoganal tRNA-aminoacyltRNA synthetase pairs |
US20030170891A1 (en) | 2001-06-06 | 2003-09-11 | Mcswiggen James A. | RNA interference mediated inhibition of epidermal growth factor receptor gene expression using short interfering nucleic acid (siNA) |
DE60234057D1 (de) | 2001-07-25 | 2009-11-26 | Raptor Pharmaceutical Inc | Zusammensetzungen und verfahren zur modulation des transports durch die blut-hirn-schranke |
US20040161776A1 (en) | 2001-10-23 | 2004-08-19 | Maddon Paul J. | PSMA formulations and uses thereof |
US7192921B2 (en) | 2001-11-08 | 2007-03-20 | The Burnham Institute | Peptides that home to tumor lymphatic vasculature and methods of using same |
DE60314495T2 (de) | 2002-02-07 | 2008-03-13 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Aminosäuresequenzen, die in der lage sind die durchdringung einer biologischen barriere zu erleichtern |
AU2003218815A1 (en) | 2002-03-29 | 2003-12-02 | Creagene Inc. | Cytoplasmic transduction peptides and uses thereof |
US6881829B2 (en) | 2002-04-26 | 2005-04-19 | Chimeracom, L.L.C. | Chimeric hybrid analgesics |
CA2487815A1 (en) | 2002-05-29 | 2003-12-11 | Symbiontics, Inc. | Targeted therapeutic proteins |
EP1539208A2 (en) | 2002-06-28 | 2005-06-15 | Nastech Pharmaceutical Company Inc. | Compositions and methods for modulating physiology of epithelial junctional adhesion molecules for enhanced mucosal delivery of therapeutic compounds |
EP2305812A3 (en) | 2002-11-14 | 2012-06-06 | Dharmacon, Inc. | Fuctional and hyperfunctional sirna |
US7829694B2 (en) | 2002-11-26 | 2010-11-09 | Medtronic, Inc. | Treatment of neurodegenerative disease through intracranial delivery of siRNA |
US7319090B2 (en) | 2002-11-27 | 2008-01-15 | University Of North Carolina At Chapel Hill | Methods of treating cerebral ischemia |
US20040102369A1 (en) | 2002-11-27 | 2004-05-27 | The Regents Of The University Of California | Transport of basic fibroblast growth factor across the blood brain barrier |
US7388079B2 (en) | 2002-11-27 | 2008-06-17 | The Regents Of The University Of California | Delivery of pharmaceutical agents via the human insulin receptor |
BRPI0406647A (pt) | 2003-01-06 | 2005-12-06 | Angiochem Inc | Método para transportar um composto através da barreira sanguìnea do cérebro |
US20040162284A1 (en) | 2003-02-19 | 2004-08-19 | Harris Herbert W. | Method of lowering body temperature with (S) tofisopam |
BRPI0409133B8 (pt) | 2003-04-08 | 2021-05-25 | Progenics Pharm Inc | preparações farmacêuticas estavéis compreendendo metilnaltrexona |
CA2520655A1 (en) | 2003-04-08 | 2004-11-04 | Biotempt, B.V. | Compositions for mucosal and oral administration comprising hcg fragments |
WO2004094595A2 (en) | 2003-04-17 | 2004-11-04 | Alnylam Pharmaceuticals Inc. | MODIFIED iRNA AGENTS |
AU2003286870A1 (en) | 2003-06-05 | 2005-01-04 | Salk Institute For Biological Studies | Targeting polypeptides to the central nervous system |
US20050026823A1 (en) | 2003-06-20 | 2005-02-03 | Biomarin Pharmaceutical Inc. | Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues |
JP5624256B2 (ja) | 2003-06-20 | 2014-11-12 | ラプター・ファーマシューティカル・インコーポレイテッド | 脳および他の組織への治療化合物の送達 |
AU2004263458B2 (en) | 2003-08-08 | 2010-06-24 | Actgen, Inc. | Polypeptides having brain-localizing activity and uses thereof |
US20070275871A1 (en) | 2003-08-28 | 2007-11-29 | Biorexis Technology, Inc. | Epo Mimetic Peptides and Fusion Proteins |
US20050058702A1 (en) | 2003-09-17 | 2005-03-17 | Ben-Sasson Shmuel A. | Compositions capable of facilitating penetration across a biological barrier |
US20050208095A1 (en) | 2003-11-20 | 2005-09-22 | Angiotech International Ag | Polymer compositions and methods for their use |
US7208174B2 (en) | 2003-12-18 | 2007-04-24 | Hoffmann-La Roche Inc. | Liposome compositions |
US7638299B2 (en) | 2004-07-21 | 2009-12-29 | Ambrx, Inc. | Biosynthetic polypeptides utilizing non-naturally encoded amino acids |
MX2007001180A (es) | 2004-07-26 | 2007-04-13 | Asterion Ltd | Enlazantes. |
WO2006039253A2 (en) | 2004-09-29 | 2006-04-13 | Children's Memorial Hospital | Sirna-mediated gene silencing of alpha synuclein |
US9002652B1 (en) | 2005-01-27 | 2015-04-07 | Institute For Systems Biology | Methods for identifying and using organ-specific proteins in blood |
ES2527634T3 (es) * | 2005-02-18 | 2015-01-27 | Angiochem Inc. | Polipéptidos de aprotinina para transportar un compuesto a través de la barrera sangre-cerebro |
KR20140016402A (ko) | 2005-02-18 | 2014-02-07 | 아브락시스 바이오사이언스, 엘엘씨 | 치료제의 조합 및 투여 방식, 및 조합 요법 |
US20090016959A1 (en) * | 2005-02-18 | 2009-01-15 | Richard Beliveau | Delivery of antibodies to the central nervous system |
US7341720B2 (en) | 2005-04-06 | 2008-03-11 | Genzyme Corporation | Targeting of glycoprotein therapeutics |
US20090246211A1 (en) | 2005-05-12 | 2009-10-01 | Henri John T | Molecular constructs suitable for targeted conjugates |
WO2006138343A2 (en) | 2005-06-14 | 2006-12-28 | Raptor Pharmaceutical Inc. | Compositions comprising receptor - associated protein (rap) variants specific for lrp2 and uses thereof |
SI2233156T1 (sl) | 2005-07-15 | 2013-09-30 | Angiochem Inc. | Uporaba polipeptidov aprotinina kot nosilce v farmacevtskih konjugatih |
BRPI0615562A2 (pt) | 2005-07-19 | 2010-01-26 | Univ Illinois | agentes de transporte para atravessamento da barreira sangue-cérebro e entrada nas células cancerìgenas do cérebro e métodos para o seu uso |
GB0517092D0 (en) | 2005-08-19 | 2005-09-28 | Novartis Ag | New compositions containing taxane derivatives |
AU2006287481A1 (en) | 2005-09-08 | 2007-03-15 | Mdrna, Inc. | Pharmaceutical compositions for delivery of ribonucleic acid to a cell |
EP1945240B1 (en) | 2005-09-16 | 2016-12-28 | Raptor Pharmaceutical Inc | Compositions comprising receptor-associated protein (rap) variants specific for cr-containing proteins and uses thereof |
WO2007103515A2 (en) | 2006-03-06 | 2007-09-13 | Amunix, Inc. | Unstructured recombinant polymers and uses thereof |
US8142781B2 (en) | 2005-10-07 | 2012-03-27 | Armagen Technologies, Inc. | Fusion proteins for blood-brain barrier delivery |
WO2007053696A2 (en) | 2005-11-01 | 2007-05-10 | Alnylam Pharmaceuticals, Inc. | Rnai inhibition of influenza virus replication |
WO2007053946A1 (en) | 2005-11-09 | 2007-05-18 | Conjuchem Biotechnologies Inc. | Method of treating diabetes and/or obesity with reduced nausea side effects using an insulinotropic peptide conjugated to albumin |
US8290433B2 (en) | 2007-11-14 | 2012-10-16 | Blaze Mobile, Inc. | Method and system for securing transactions made through a mobile communication device |
AR054215A1 (es) | 2006-01-20 | 2007-06-13 | Eriochem Sa | Una formulacion farmaceutica de un taxano, una composicion solida de un taxano liofilizado a partir de una solucion de acido acetico, un procedimiento para la preparacion de dicha composicion solida de un taxano, una composicion solubilizante de un taxano liofilizado, y un conjunto de elementos (kit |
US7477504B1 (en) | 2006-03-13 | 2009-01-13 | C.P.D. Technologies, Inc. | Versatile stun glove |
PL2177536T3 (pl) | 2006-03-30 | 2014-11-28 | Glaxo Group Ltd | Przeciwciała przeciwko peptydowi beta-amyloidu |
JP2009543806A (ja) | 2006-07-13 | 2009-12-10 | バーナム インスティテュート フォー メディカル リサーチ | gC1qR/p32を標的化するための方法および組成物 |
ES2371495T3 (es) | 2006-07-24 | 2012-01-03 | Biorexis Pharmaceutical Corporation | Proteínas de fusión de exendina. |
EP2063905B1 (en) | 2006-09-18 | 2014-07-30 | Raptor Pharmaceutical Inc | Treatment of liver disorders by administration of receptor-associated protein (rap)-conjugates |
CA2666841A1 (en) | 2006-10-19 | 2008-04-24 | Angiochem, Inc. | Compounds for stimulating p-glycoprotein function and uses thereof |
WO2008069876A2 (en) | 2006-10-27 | 2008-06-12 | University Of Kentucky Research Foundation | Amidated dopamine neuron stimulating peptides for cns dopaminergic upregulation |
US9399675B2 (en) | 2007-02-28 | 2016-07-26 | The Board Of Regents Of The University Of Oklahoma | Methods and compositions for diagnosing Alzheimer's disease and age-related macular degeneration |
WO2008116171A1 (en) | 2007-03-21 | 2008-09-25 | Raptor Pharmaceutical Inc. | Cyclic receptor-associated protein (rap) peptides |
US9365634B2 (en) | 2007-05-29 | 2016-06-14 | Angiochem Inc. | Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues |
WO2008144919A1 (en) * | 2007-05-29 | 2008-12-04 | Angiochem, Inc. | Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues |
US8802631B2 (en) | 2007-09-17 | 2014-08-12 | Ludwig Institute For Cancer Research Ltd. | Peptides and methods for the treatment of gliomas and other cancers |
NZ584048A (en) | 2007-10-02 | 2012-08-31 | Marina Biotech Inc | Lipopeptides for delivery of nucleic acids |
WO2009070597A2 (en) | 2007-11-26 | 2009-06-04 | Armagen Technologies, Inc. | Fusion proteins for delivery of gdnf to the cns |
BRPI0821310A2 (pt) | 2007-12-20 | 2015-06-16 | Angiochem Inc | Conjugados polipeptídeos-ácido nucleico e usos dos mesmos |
US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
CA2713872A1 (en) | 2008-02-21 | 2009-08-27 | Burnham Institute For Medical Research | Methods and compositions related to peptides and proteins with c-terminal elements |
JP5860698B2 (ja) | 2008-04-18 | 2016-02-16 | アンジオケム,インコーポレーテッド | パクリタキセル、パクリタキセル類似体またはパクリタキセルコンジュゲートの医薬組成物ならびに関連する調製方法および使用方法 |
US8921314B2 (en) | 2008-10-15 | 2014-12-30 | Angiochem, Inc. | Conjugates of GLP-1 agonists and uses thereof |
RU2531591C2 (ru) | 2008-10-15 | 2014-10-20 | Ангиокем Инк. | Конъюгаты этопозида и доксорубицина для доставки лекарственных средств |
CN102272163A (zh) | 2008-12-05 | 2011-12-07 | 安吉奥开米公司 | 瘦素和瘦素类似物结合物及其用途 |
CN102307904A (zh) | 2008-12-05 | 2012-01-04 | 安吉奥开米公司 | 神经降压素或神经降压素类似物的缀合物及其用途 |
CA2745499A1 (en) | 2008-12-05 | 2010-06-10 | Angiochem Inc. | Peptide therapeutic conjugates and uses thereof |
JP2012512185A (ja) | 2008-12-17 | 2012-05-31 | アンジオケム インコーポレーテッド | 膜1型マトリックス金属タンパク質阻害剤およびその使用 |
CA2759129C (en) | 2009-04-20 | 2018-12-11 | Angiochem Inc. | Treatment of ovarian cancer using an anticancer agent conjugated to an angiopep-2 analog |
US20100284921A1 (en) | 2009-05-08 | 2010-11-11 | Temple University - Of The Commonwealth System Of Higher Education | Targeted nanoparticles for intracellular cancer therapy |
US20110111056A1 (en) | 2009-06-03 | 2011-05-12 | Dicerna Pharmaceuticals, Inc. | Peptide dicer substrate agents and methods for their specific inhibition of gene expression |
CN102459348A (zh) | 2009-06-11 | 2012-05-16 | 安吉奥开米公司 | 用于将gdnf和bdnf递送至中枢神经***的融合蛋白 |
AU2010268726A1 (en) | 2009-07-02 | 2012-01-19 | Angiochem Inc. | Multimeric peptide conjugates and uses thereof |
HUE026708T2 (en) | 2009-07-14 | 2016-07-28 | Mayo Foundation | Peptide-mediated, non-covalent delivery of active substances in blood glucose |
CN102781965A (zh) | 2009-10-06 | 2012-11-14 | 安吉奥开米公司 | 用于转运治疗剂的组合物和方法 |
US8530429B2 (en) | 2009-11-24 | 2013-09-10 | Arch Cancer Therapeutics, Inc. | Brain tumor targeting peptides and methods |
US9095541B2 (en) | 2009-11-24 | 2015-08-04 | Arch Cancer Therapeutics, Inc. | Brain tumor targeting peptides and methods |
EP2333074A1 (en) | 2009-12-14 | 2011-06-15 | Robert Steinfeld | Substances and methods for the treatment of lysosmal storage diseases |
JP5827962B2 (ja) | 2010-03-08 | 2015-12-02 | スローン ケタリング インスティテュート フォア キャンサー リサーチ | Cdc7キナーゼ阻害剤およびその使用 |
EP2550285B1 (en) | 2010-03-22 | 2017-07-19 | President and Fellows of Harvard College | Trioxacarcins and uses thereof |
WO2011119608A1 (en) | 2010-03-26 | 2011-09-29 | University Of Tennessee Research Foundation | Peptides that specifically target amyloid deposits |
EP2558503B1 (en) | 2010-04-14 | 2015-12-09 | National Research Council of Canada | Compositions and methods for brain delivery of analgesic peptides |
WO2011153642A1 (en) | 2010-06-10 | 2011-12-15 | Angiochem Inc. | Leptin and leptin analog conjugates and fusion proteins and uses thereof |
JP2013530993A (ja) | 2010-07-02 | 2013-08-01 | アンジオケム インコーポレーテッド | 治療用コンジュゲートのための短く且つd−アミノ酸を含有するポリペプチドおよびその使用 |
US8218280B2 (en) | 2010-07-08 | 2012-07-10 | Schneider Electric USA, Inc. | Secondary thermal sensor for primary conductors |
WO2012018404A2 (en) | 2010-08-06 | 2012-02-09 | U3 Pharma Gmbh | Use of her3 binding agents in prostate treatment |
CN102406949B (zh) | 2010-09-21 | 2013-05-29 | 复旦大学 | 一种靶向示踪的多模式诊断纳米影像药物 |
WO2012037687A1 (en) | 2010-09-23 | 2012-03-29 | Angiochem Inc. | Therapeutic polypeptides and uses thereof |
CN103298474B (zh) | 2010-11-10 | 2016-06-29 | 无限药品股份有限公司 | 杂环化合物及其用途 |
RU2013127625A (ru) | 2010-11-18 | 2014-12-27 | Зе Дженерал Хоспитал Корпорейшен | Новые композиции и применения антигипертензивных средств для терапии рака |
CN102552928A (zh) | 2010-12-19 | 2012-07-11 | 复旦大学 | 一种治疗脑部肿瘤的双级靶向递药***及其制备方法 |
WO2012097000A1 (en) | 2011-01-10 | 2012-07-19 | Pingda Ren | Processes for preparing isoquinolinones and solid forms of isoquinolinones |
CN102614105A (zh) | 2011-01-28 | 2012-08-01 | 复旦大学 | 一种脑靶向载两性霉素b聚合物胶束给药*** |
JP2014506922A (ja) | 2011-03-01 | 2014-03-20 | ティーオー − ビービービー ホールディング ベスローテン フェンノートシャップ | 難水溶性物質の高度なアクティブリポソームローディング |
EP2691443B1 (en) | 2011-03-28 | 2021-02-17 | Massachusetts Institute of Technology | Conjugated lipomers and uses thereof |
EP2696898A4 (en) | 2011-04-07 | 2014-10-01 | Univ Emory | COMPOSITIONS COMPRISING SACCHARIDE BINDING FRACTIONS AND METHODS FOR TARGETED THERAPY |
US20140213641A1 (en) | 2011-05-09 | 2014-07-31 | Institut Quimic De Sarria | Polymeric nanoparticles for drug delivery |
WO2013004716A1 (en) | 2011-07-04 | 2013-01-10 | Universität Basel | Peptide beads |
EP2734530A1 (en) | 2011-07-19 | 2014-05-28 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
EP2734520B1 (en) | 2011-07-19 | 2016-09-14 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
EP2741749A4 (en) | 2011-08-11 | 2015-04-15 | Intellikine Llc | KINASE-INHIBITING POLYMORPH |
CA2846431A1 (en) | 2011-08-29 | 2013-03-07 | Infinity Pharmaceuticals Inc. | Heterocyclic compounds and uses thereof |
US9630979B2 (en) | 2011-09-29 | 2017-04-25 | Infinity Pharmaceuticals, Inc. | Inhibitors of monoacylglycerol lipase and methods of their use |
WO2013056096A1 (en) | 2011-10-13 | 2013-04-18 | Angiochem Inc. | Polypeptide-opioid conjugates and uses thereof |
PE20150041A1 (es) | 2011-10-27 | 2015-01-28 | Massachusetts Inst Technology | Derivados de aminoacidos funcionalizados en la terminal n capaces de formar microesferas encapsuladoras de farmaco |
WO2013071272A1 (en) | 2011-11-11 | 2013-05-16 | Intellikine, Llc | Kinase inhibitor polymorphs |
US20150037311A1 (en) | 2011-12-01 | 2015-02-05 | Angiochem Inc. | Targeted lysosomal enzyme compounds |
CN104136606A (zh) | 2011-12-01 | 2014-11-05 | 安吉奥开米公司 | 靶向的艾杜糖-2-硫酸酯酶化合物 |
MX359410B (es) | 2011-12-13 | 2018-09-27 | Engeneic Molecular Delivery Pty Ltd | Minicélulas intactas derivadas bacterialmente para suministro de agentes terapéuticos a tumores cerebrales. |
EP2791210A1 (en) | 2011-12-16 | 2014-10-22 | Massachusetts Institute of Technology | Alpha-aminoamidine polymers and uses thereof |
WO2013120107A1 (en) | 2012-02-09 | 2013-08-15 | University Of Rochester | Methods and compositions for treating a subject to inhibit hearing loss |
EP3153523A3 (en) | 2012-03-02 | 2017-05-03 | Icahn School of Medicine at Mount Sinai | Variants of prothymosin alpha and methods of using same |
JP6042527B2 (ja) | 2012-04-04 | 2016-12-14 | ハロザイム インコーポレイテッド | 抗ヒアルロナン剤と腫瘍標的タキサンの組み合わせ治療 |
US9745334B2 (en) | 2012-04-26 | 2017-08-29 | Yale University | Cytotoxic-drug delivering molecules targeting HIV (CDM-Hs), cytotoxic activity against the human immunodeficiency virus and methods of use |
-
2010
- 2010-04-20 CA CA2759129A patent/CA2759129C/en active Active
- 2010-04-20 BR BRPI1015295A patent/BRPI1015295A2/pt not_active IP Right Cessation
- 2010-04-20 MX MX2011011023A patent/MX2011011023A/es not_active Application Discontinuation
- 2010-04-20 US US13/265,309 patent/US9173891B2/en not_active Expired - Fee Related
- 2010-04-20 CN CN2010800275644A patent/CN102510759A/zh active Pending
- 2010-04-20 WO PCT/CA2010/000618 patent/WO2010121379A1/en active Application Filing
- 2010-04-20 ES ES10766565T patent/ES2729261T3/es active Active
- 2010-04-20 AU AU2010239069A patent/AU2010239069B2/en not_active Expired - Fee Related
- 2010-04-20 EP EP10766565.5A patent/EP2421562B1/en not_active Not-in-force
- 2010-04-20 JP JP2012505012A patent/JP2012524030A/ja not_active Ceased
- 2010-04-20 RU RU2011146654/15A patent/RU2011146654A/ru not_active Application Discontinuation
-
2011
- 2011-10-18 ZA ZA2011/07626A patent/ZA201107626B/en unknown
Also Published As
Publication number | Publication date |
---|---|
ES2729261T3 (es) | 2019-10-31 |
WO2010121379A1 (en) | 2010-10-28 |
EP2421562B1 (en) | 2019-03-13 |
AU2010239069B2 (en) | 2015-05-14 |
US20120122798A1 (en) | 2012-05-17 |
JP2012524030A (ja) | 2012-10-11 |
CA2759129A1 (en) | 2010-10-28 |
CA2759129C (en) | 2018-12-11 |
CN102510759A (zh) | 2012-06-20 |
ZA201107626B (en) | 2012-12-27 |
EP2421562A1 (en) | 2012-02-29 |
MX2011011023A (es) | 2012-01-20 |
BRPI1015295A2 (pt) | 2016-05-31 |
EP2421562A4 (en) | 2014-12-10 |
AU2010239069A1 (en) | 2011-11-10 |
US9173891B2 (en) | 2015-11-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2011146654A (ru) | Способы лечения рака яичников с применением конъюгированного средства | |
Brown et al. | Cisplatin-based chemotherapy of human cancers | |
Mehmood | Review of Cisplatin and oxaliplatin in current immunogenic and monoclonal antibody treatments | |
Liu et al. | Inhibition of tumor growth in vitro by a combination of extracts from rosa roxburghii tratt and fagopyrum cymosum | |
Karnthaler‐Benbakka et al. | Tumor‐targeting of EGFR inhibitors by hypoxia‐mediated activation | |
RU2011142806A (ru) | Комбинации пентамидина для лечения рака | |
RU2012137503A (ru) | Лекарственный препарат для лечения и/или профилактики рака | |
RU2014108044A (ru) | Фармацевтическая композиция для лечения и профилактики злокачественной опухоли | |
RU2014108049A (ru) | Фармацевтическая композиция для лечения и/или профилактики злокачественной опухоли | |
RU2014108045A (ru) | Фармацевтическая композиция для лечения и/или профилактики злокачественной опухоли | |
RU2014108043A (ru) | Фармацевтическая композиция для лечения и/или профилактики злокачественной опухоли | |
Chen et al. | A new prospect in cancer therapy: targeting cancer stem cells to eradicate cancer | |
Soleyman-Jahi et al. | In vitro assessment of antineoplastic effects of deuterium depleted water | |
Sangermano et al. | Y box binding protein 1 (YB-1) oncoprotein at the hub of DNA proliferation, damage and cancer progression | |
RU2015141932A (ru) | Аргининдеиминаза с пониженной перекрестной реактивностью к антителам adi-peg 20 для лечения рака | |
EA201892797A1 (ru) | Наночастицы для доставки лекарственных средств и способы лечения лекарственно-резистентного рака | |
Yu et al. | Eradication of growth of HER2-positive ovarian cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate in mouse xenograft model | |
RU2015152785A (ru) | Лечение злокачественной опухоли налтрексоном | |
JP2017529366A5 (ru) | ||
RU2014148171A (ru) | Средство для профилактического и/или терапевтического лечения периферической нейропатической боли, вызываемой противораковым средством | |
RU2009127775A (ru) | Способ введения пегилированного липосомального доксорубицина | |
Qi et al. | Cisplatin loaded multiwalled carbon nanotubes reverse drug resistance in NSCLC by inhibiting EMT | |
Wang et al. | HER-2-mediated nano-delivery of molecular targeted drug potently suppresses orthotopic epithelial ovarian cancer and metastasis | |
Imai et al. | Efficacy and safety of carboplatin and etoposide combination chemotherapy for extrapulmonary neuroendocrine carcinoma: a retrospective case series | |
RU2019134769A (ru) | Композиции для лечения резистентных к лекарственным средствам опухолей и способы их применения |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA94 | Acknowledgement of application withdrawn (non-payment of fees) |
Effective date: 20160704 |